ASCRS 2024: A case report on human corneal endothelial cell transplantation combined with cataract extraction and PCIOL

News
Video

Elizabeth Yeu, MD, discusses a corneal case report at ASCRS 2024

At this year's ASCRS meeting, we spoke with Elizabeth Yeu, MD, as she concluded her term as president of the ASCRS. In this video, she discusses a case report, detailing how the triple procedure can be beneficial for different patient populations. The data discussed are from her ASCRS presentation, 'Human corneal endothelial cell transplantation combined with cataract extraction and PCIOL in subject with corneal oedema.'

Editor's note: The below transcript has been lightly edited for clarity.

Hi, my name is Elizabeth Yeu. I'm a cornea, cataract and refractive surgeon at Virginia Eye Consultants. I have been so fortunate to be involved with the Aurion clinical trials, which we were able to do the phase 1 and 2 studies in El Salvador to make sure that we were looking at the human corneal endothelial cells [CEC] with a proprietary ROCK [rho-kinase] inhibitor and find out the right dosing. But at the same time, we were also able to help with different patient populations.

In doing so we were able to help certain patients, for example, an 85-year-old patient who had a very significant cataract with 20/800 vision and a 700-micron cornea. And this patient certainly needed to have some kind of procedure where we could take care of both at the same time. In the US, obviously, this would be a patient that's standard of care who would absolutely be considered an an EK [endothelial keratoplasty] procedure at the same time with a combined cataract surgery. So absolutely recognising that having done multiple corneal endothelial cell injection therapy patients and seeing the results of that, we said, well, absolutely, let's do the cataract surgery and consider a triple procedure, see how this patient does because we know how successful the CEC therapies have been for our patients.

So thus, we did perform for this 20/800 patient with a significant cataract and a thickened cornea, a triple procedure doing the phacoemulsification and the human corneal endothelial cell injection therapy that also had the ROCK inhibitor.

And lo and behold, absolutely wonderful results that we could see. In terms of any differences in the way that surgical procedure was performed, absolutely not. Just a routine cataract surgery for a mature brunescent lens. And at the end of the procedure, we perform the normal injection therapy of the cells as we normally would have after bringing the pupil down.

And after 2 months, there was a 200 micron decrease in the corneal thickness from 700 microns down to 500 microns. And the patient by post-op month 6–there was gradual improvement of vision–but the patient by post-op month 6 was 20/25 with a 500-micron cornea from limbus to limbus.

These patients look like none other. It is completely different than the kind of patients we see with allograft postoperative cadaveric donor corneas, because it is not just clearing of the central 70% of the cornea. It is limbus to limbus clearing and 500 microns of glistening pure clearing of the full 11 to 12 diameter cornea.

It is completely life altering for these patients that we see postoperatively and it just makes you realise that we are going to be able to potentially change the way that we are able to help our patients in the US, in the future, globally as well, for our visually significant cataracts who also have have visually significant endothelial disease.

It's very promising therapy for both our pseudophakic as well as our phakic patients who have significant endothelial damaged corneas. Thank you.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.